BRIEF—$100 million IPO for oral inhibitor startup Principia Biopharma

Principia Biopharma, a startup based in southern San Francisco, has raised over $100 million in an initial public offering, kicking off trading on the Nasdaq on September 14.

The clinical-stage pharma firm is working on oral therapies for patients with significant unmet medical needs in immunology and oncology.

The firm has a proprietary platform for designing and developing small molecule inhibitors which it says will have “potencies and selectivities that have the potential to rival those of injectable biologics, yet maintain the convenience of a pill.”